Compositions and methods for the treatment of tumor of hematopoietic origin

Isolated nucleic acid having a nucleotide sequence that has at least 95% nucleic acid sequence identity to:

• (a) a DNA molecule encoding the amino acid sequence selected from the group consisting of the amino acid sequence shown in FIG. 2 (SEQ ID NO:
• 2), FIG. 4 (SEQ ID NO:
• 4) and FIG. 6 (SEQ ID NO:
• 6);
• (b) a DNA molecule encoding the amino acid sequence selected from the group consisting of the amino acid sequence shown in FIG. 2 (SEQ ID NO:
• 2), FIG. 4 (SEQ ID NO:
• 4) and FIG. 6 (SEQ ID NO:
• 6), lacking its associated signal peptide;
• (c) a DNA molecule encoding an extracellular domain of the polypeptide having the amino acid selected from the group consisting of the amino acid sequence shown in FIG. 2 (SEQ ID NO:
• 2), FIG. 4 (SEQ ID NO:
• 4) and FIG. 6 (SEQ ID NO:
• 6), with its associated signal peptide;
• (d) a DNA molecule encoding an extracellular domain of the polypeptide having the amino acid selected from the group consisting of the amino acid sequence shown in FIG. 2 (SEQ ID NO:
• 2), FIG. 4 (SEQ ID NO:
• 4) and FIG. 6 (SEQ ID NO:
• 6), lacking its associated signal peptide;
• (e) the nucleotide sequence selected from the group consisting of the nucleotide sequence shown in FIG. 1 (SEQ ID NO:
• 1), FIG. 3 (SEQ ID NO:3) and FIG. 5 (SEQ ID NO:
• 5);
• (f) the full-length coding region of the nucleotide sequence selected from the group consisting of the nucleotide sequence shown in FIG. 1 (SEQ ID NO:
• 1), FIG. 3 (SEQ ID NO:3) and FIG. 5 (SEQ ID NO:
• 5);
• or
• (g) the complement of (a), (b), (c), (d), (e) or (f).

Isolated nucleic acid having:

• (a) a nucleotide sequence that encodes the amino acid sequence selected from the group consisting of the amino acid sequence shown in FIG. 2 (SEQ ID NO:
• 2), FIG. 4 (SEQ ID NO:
• 4) and FIG. 6 (SEQ ID NO:
• 6);
• (b) a nucleotide sequence that encodes the amino acid sequence selected from the group consisting of the amino acid sequence shown in FIG. 2 (SEQ ID NO:
• 2), FIG. 4 (SEQ ID NO:
• 4) and FIG. 6 (SEQ ID NO:
• 6), lacking its associated signal peptide;
• (c) a nucleotide sequence that encodes an extracellular domain of the polypeptide having the amino acid selected from the group consisting of the amino acid sequence shown in FIG. 2 (SEQ ID NO:
• 2), FIG. 4 (SEQ ID NO:
• 4) and FIG. 6 (SEQ ID NO:
• 6), with its associated signal peptide;
• (d) a nucleotide sequence that encodes an extracellular domain of the polypeptide having the amino acid selected from the group consisting of the amino acid sequence shown in FIG. 2 (SEQ ID NO:
• 2), FIG. 4 (SEQ ID NO:
• 4) and FIG. 6 (SEQ ID NO:
• 6), lacking its associated signal peptide;
• (e) the nucleotide sequence selected from the group consisting of the nucleotide sequence shown in FIG. 1 (SEQ ID NO:
• 1) and FIG. 3 (SEQ ID NO:3);
• (f) the full-length coding region of the nucleotide sequence selected from the group consisting of the nucleotide sequence shown in FIG. 1 (SEQ ID NO:
• 1), FIG. 3 (SEQ ID NO:3) and FIG. 5 (SEQ ID NO:
• 5);
• or
• (g) the complement of (a), (b), (c), (d), (e) or (f).

Isolated nucleic acid that hybridizes to:

• (a) a nucleic acid that encodes the amino acid sequence selected from the group consisting of the amino acid sequence shown in FIG. 2 (SEQ ID NO:
• 2), FIG. 4 (SEQ ID NO:
• 4) and FIG. 6 (SEQ ID NO:
• 6);
• (b) a nucleic acid that encodes the amino acid sequence selected from the group consisting of the amino acid sequence shown in FIG. 2 (SEQ ID NO:
• 2), FIG. 4 (SEQ ID NO:
• 4) and FIG. 6 (SEQ ID NO:
• 6), lacking its associated signal peptide;
• (c) a nucleic acid that encodes an extracellular domain of the polypeptide having the amino acid sequence selected from the group consisting of the amino acid sequence shown FIG. 2 (SEQ ID NO:
• 2), FIG. 4 (SEQ ID NO:
• 4) and FIG. 6 (SEQ ID NO:
• 6), with its associated signal peptide;
• (d) a nucleic acid that encodes an extracellular domain of the polypeptide having the amino acid sequence selected from the group consisting of the amino acid sequence shown in FIG. 2 (SEQ ID NO:
• 2), FIG. 4 (SEQ ID NO:
• 4) and FIG. 6 (SEQ ID NO:
• 6), lacking its associated signal peptide;
• (e) the nucleotide sequence selected from the group consisting of the nucleotide sequence shown in FIG. 1 (SEQ ID NO:
• 1), FIG. 3 (SEQ ID NO:3) and FIG. 5 (SEQ ID NO:
• 5);
• (f) the full-length coding region of the nucleotide sequence selected from the group consisting of the nucleotide sequence shown in FIG. 1 (SEQ ID NO:
• 1), FIG. 3 (SEQ ID NO:3) and FIG. 5 (SEQ ID NO:
• 5);
• or
• (g) the complement of (a), (b), (c), (d), (e) or (f).

An isolated polypeptide having at least 95% amino acid sequence identity to:

• (a) the polypeptide having the amino acid sequence selected from the group consisting of the amino acid sequence shown in FIG. 2 (SEQ ID NO:
• 2), FIG. 4 (SEQ ID NO:
• 4) and FIG. 6 (SEQ ID NO:
• 6);
• (b) the polypeptide having the amino acid sequence selected from the group consisting of the amino acid sequence shown in FIG. 2 (SEQ ID NO:
• 2), FIG. 4 (SEQ ID NO:
• 4) and FIG. 6 (SEQ ID NO:
• 6), lacking its associated signal peptide;
• (c) an extracellular domain of the polypeptide having the amino acid sequence selected from the group consisting of the amino acid sequence shown in FIG. 2 (SEQ ID NO:
• 2), FIG. 4 (SEQ ID NO:
• 4) and FIG. 6 (SEQ ID NO:
• 6), with its associated signal peptide;
• (d) an extracellular domain of the polypeptide having the amino acid sequence selected from the group consisting of the amino acid sequence shown in FIG. 2 (SEQ ID NO:
• 2), FIG. 4 (SEQ ID NO:
• 4) and FIG. 6 (SEQ ID NO:
• 6) lacking its associated signal peptide;
• (e) a polypeptide encoded by the nucleotide sequence selected from the group consisting of the nucleotide sequence shown in FIG. 1 (SEQ ID NO:
• 1), FIG. 3 (SEQ ID NO:3) and FIG. 5 (SEQ ID NO:
• 5);
• or
• (f) a polypeptide encoded by the full-length coding region of the nucleotide sequence selected from the group consisting of the nucleotide sequence shown in FIG. 1 (SEQ ID NO:
• 1), FIG. 3 (SEQ ID NO:3) and FIG. 5 (SEQ ID NO:
• 5).

An isolated polypeptide having:

• (a) the amino acid sequence selected from the group consisting of the amino acid sequence shown in FIG. 2 (SEQ ID NO:
• 2), FIG. 4 (SEQ ID NO:
• 4) and FIG. 6 (SEQ ID NO:
• 6);
• (b) the amino acid sequence selected from the group consisting of the amino acid sequence shown in FIG. 2 (SEQ ID NO:
• 2), FIG. 4 (SEQ ID NO:
• 4) and FIG. 6 (SEQ ID NO:
• 6), lacking its associated signal peptide sequence;
• (c) an amino acid sequence of an extracellular domain of the polypeptide selected from the group consisting of the amino acid sequence shown in FIG. 2 (SEQ ID NO:
• 2), FIG. 4 (SEQ ID NO:
• 4) and FIG. 6 (SEQ ID NO:
• 6), with its associated signal peptide sequence;
• (d) an amino acid sequence of an extracellular domain of the polypeptide selected from the group consisting of the amino acid sequence shown in FIG. 2 (SEQ ID NO:
• 2), FIG. 4 (SEQ ID NO:
• 4) and FIG. 6 (SEQ ID NO:
• 6), lacking its associated signal peptide sequence;
• (e) an amino acid sequence encoded by the nucleotide sequence selected from the group consisting of the nucleotide sequence shown in FIG. 1 (SEQ ID NO:
• 1), FIG. 3 (SEQ ID NO:
• 3) and FIG. 5 (SEQ ID NO:
• 5);
• or
• (f) an amino acid sequence encoded by the full-length coding region of the nucleotide sequence selected from the group consisting of the nucleotide sequence shown in FIG. 1 (SEQ ID NO:
• 1), FIG. 3 (SEQ ID NO:
• 3) and FIG. 5 (SEQ ID NO:
• 5).

An isolated antibody that binds to a polypeptide having at least 95% amino acid sequence identity to:

• (a) the polypeptide having the amino acid sequence selected from the group consisting of the amino acid sequence shown in FIG. 2 (SEQ ID NO:
• 2), FIG. 4 (SEQ ID NO:
• 4) and FIG. 6 (SEQ ID NO:
• 6);
• (b) the polypeptide selected from the group consisting of the amino acid sequence shown in FIG. 2 (SEQ ID NO:
• 2), FIG. 4 (SEQ ID NO:
• 4) and FIG. 6 (SEQ ID NO:
• 6), lacking its associated signal peptide;
• (c) an extracellular domain of the polypeptide having the amino acid sequence selected from the group consisting of the amino acid sequence shown in FIG. 2 (SEQ ID NO:
• 2), FIG. 4 (SEQ ID NO:
• 4) and FIG. 6 (SEQ ID NO:
• 6), with its associated signal peptide;
• (d) an extracellular domain of the polypeptide having the amino acid sequence selected from the group consisting of the amino acid sequence shown in FIG. 2 (SEQ ID NO:
• 2), FIG. 4 (SEQ ID NO:
• 4) and FIG. 6 (SEQ ID NO:
• 6), lacking its associated signal peptide;
• (e) a polypeptide encoded by the nucleotide sequence selected from the group consisting of the nucleotide sequence shown in FIG. 1 (SEQ ID NO:
• 1), FIG. 3 (SEQ ID NO:3) and FIG. 5 (SEQ ID NO:
• 5);
• or
• (f) a polypeptide encoded by the full-length coding region of the nucleotide sequence selected from the group consisting of the nucleotide sequence shown in FIG. 1 (SEQ ID NO:
• 1), FIG. 3 (SEQ ID NO:3) and FIG. 5 (SEQ ID NO:
• 5).

An isolated antibody that binds to a polypeptide having:

• (a) the amino acid sequence selected from the group consisting of the amino acid sequence shown in FIG. 2 (SEQ ID NO:
• 2), FIG. 4 (SEQ ID NO:
• 4) and FIG. 6 (SEQ ID NO:
• 6);
• (b) the amino acid sequence selected from the group consisting of the amino acid sequence shown in FIG. 2 (SEQ ID NO:
• 2), FIG. 4 (SEQ ID NO:
• 4) and FIG. 6 (SEQ ID NO:
• 6), lacking its associated signal peptide sequence;
• (c) an amino acid sequence of an extracellular domain of the polypeptide selected from the group consisting of the amino acid sequence shown in FIG. 2 (SEQ ID NO:
• 2), FIG. 4 (SEQ ID NO:
• 4) and FIG. 6 (SEQ ID NO:
• 6), with its associated signal peptide sequence;
• (d) an amino acid sequence of an extracellular domain of the polypeptide selected from the group consisting of the amino acid sequence shown in FIG. 2 (SEQ ID NO:
• 2), FIG. 4 (SEQ ID NO:
• 4) and FIG. 6 (SEQ ID NO:
• 6), lacking its associated signal peptide sequence;
• (e) an amino acid sequence encoded by the nucleotide sequence selected from the group consisting of the nucleotide sequence shown in FIG. 1 (SEQ ID NO:
• 1), FIG. 3 (SEQ ID NO:
• 3) and FIG. 5 (SEQ ID NO:
• 5);
• or
• (f) an amino acid sequence encoded by the full-length coding region of the nucleotide sequence selected from the group consisting of the nucleotide sequence shown in FIG. 1 (SEQ ID NO:
• 1), FIG. 3 (SEQ ID NO:
• 3) and FIG. 5 (SEQ ID NO:
• 5).

An isolated oligopeptide that binds to a polypeptide having at least 95% amino acid sequence identity to:

• (a) the polypeptide having the amino acid sequence selected from the group consisting of the amino acid sequence shown in FIG. 2 (SEQ ID NO:
• 2), FIG. 4 (SEQ ID NO:
• 4) and FIG. 6 (SEQ ID NO:
• 6);
• (b) the polypeptide having the amino acid sequence selected from the group consisting of the amino acid sequence shown in FIG. 2 (SEQ ID NO:
• 2), FIG. 4 (SEQ ID NO:
• 4) and FIG. 6 (SEQ ID NO:
• 6), lacking its associated signal peptide;
• (c) an extracellular domain of the polypeptide having the amino acid sequence selected from the group consisting of the amino acid sequence shown in FIG. 2 (SEQ ID NO:
• 2), FIG. 4 (SEQ ID NO:
• 4) and FIG. 6 (SEQ ID NO:
• 6), with its associated signal peptide;
• (d) an extracellular domain of the polypeptide having the amino acid sequence selected from the group consisting of the amino acid sequence shown in FIG. 2 (SEQ ID NO:
• 2), FIG. 4 (SEQ ID NO:
• 4) and FIG. 6 (SEQ ID NO:
• 6), lacking its associated signal peptide;
• (e) a polypeptide encoded by the nucleotide sequence selected from the group consisting of the nucleotide sequence shown in FIG. 1 (SEQ ID NO:
• 1), FIG. 3 (SEQ ID NO:3) and FIG. 5 (SEQ ID NO:
• 5);
• or
• (f) a polypeptide encoded by the full-length coding region of the nucleotide sequence selected from the group consisting of the nucleotide sequence shown in FIG. 1 (SEQ ID NO:
• 1), FIG. 3 (SEQ ID NO:3) and FIG. 5 (SEQ ID NO:
• 5).

An isolated oligopeptide that binds to a polypeptide having:

• (a) the amino acid sequence selected from the group consisting of the amino acid sequence shown in FIG. 2 (SEQ ID NO:
• 2), FIG. 4 (SEQ ID NO:
• 4) and FIG. 6 (SEQ ID NO:
• 6);
• (b) the amino acid sequence selected from the group consisting of the amino acid sequence shown in FIG. 2 (SEQ ID NO:
• 2), FIG. 4 (SEQ ID NO:
• 4) and FIG. 6 (SEQ ID NO:
• 6), lacking its associated signal peptide sequence;
• (c) an amino acid sequence of an extracellular domain of the polypeptide selected from the group consisting of the amino acid sequence shown in FIG. 2 (SEQ ID NO:
• 2), FIG. 4 (SEQ ID NO:
• 4) and FIG. 6 (SEQ ID NO:
• 6), with its associated signal peptide sequence;
• (d) an amino acid sequence of an extracellular domain of the polypeptide selected from the group consisting of the amino acid sequence shown in FIG. 2 (SEQ ID NO:
• 2), FIG. 4 (SEQ ID NO:
• 4) and FIG. 6 (SEQ ID NO:
• 6), lacking its associated signal peptide sequence;
• (e) an amino acid sequence encoded by the nucleotide sequence selected from the group consisting of the nucleotide sequence shown in FIG. 1 (SEQ ID NO:
• 1), FIG. 3 (SEQ ID NO:3) and FIG. 5 (SEQ ID NO:
• 5);
• or
• (f) an amino acid sequence encoded by the full-length coding region of the nucleotide sequence selected from the group consisting of the nucleotide sequence shown in FIG. 1 (SEQ ID NO:
• 1), FIG. 3 (SEQ ID NO:3) and FIG. 5 (SEQ ID NO:
• 5).

A TAHO binding organic molecule that binds to a polypeptide having at least 95% amino acid sequence identity to:

• (a) the polypeptide having the amino acid sequence selected from the group consisting of the amino acid sequence shown in FIG. 2 (SEQ ID NO:
• 2), FIG. 4 (SEQ ID NO:
• 4) and FIG. 6 (SEQ ID NO:
• 6);
• (b) the polypeptide having the amino acid sequence selected from the group consisting of the amino acid sequence shown in FIG. 2 (SEQ ID NO:
• 2), FIG. 4 (SEQ ID NO:
• 4) and FIG. 6 (SEQ ID NO:
• 6), lacking its associated signal peptide;
• (c) an extracellular domain of the polypeptide having the amino acid sequence selected from the group consisting of the amino acid sequence shown in FIG. 2 (SEQ ID NO:
• 2), FIG. 4 (SEQ ID NO:
• 4) and FIG. 6 (SEQ ID NO:
• 6), with its associated signal peptide;
• (d) an extracellular domain of the polypeptide having the amino acid sequence selected from the group consisting of the amino acid sequence shown in FIG. 2 (SEQ ID NO:
• 2), FIG. 4 (SEQ ID NO:
• 4) and FIG. 6 (SEQ ID NO:
• 6), lacking its associated signal peptide;
• (e) a polypeptide encoded by the nucleotide sequence selected from the group consisting of the nucleotide sequence shown in FIG. 1 (SEQ ID NO:
• 1), FIG. 3 (SEQ ID NO:3) and FIG. 5 (SEQ ID NO:
• 5);
• or
• (f) a polypeptide encoded by the full-length coding region of the nucleotide sequence selected from the group consisting of the nucleotide sequence shown in FIG. 1 (SEQ ID NO:
• 1), FIG. 3 (SEQ ID NO:3) and FIG. 5 (SEQ ID NO:
• 5).

A method of inhibiting the growth of a cell that expresses a protein having at least 95% amino acid sequence identity to:

• (a) the polypeptide having the amino acid sequence selected from the group consisting of the amino acid sequence shown in FIG. 2 (SEQ ID NO:
• 2), FIG. 4 (SEQ ID NO:
• 4) and FIG. 6 (SEQ ID NO:
• 6);
• (b) the polypeptide having the amino acid sequence selected from the group consisting of the amino acid sequence shown in FIG. 2 (SEQ ID NO:
• 2), FIG. 4 (SEQ ID NO:
• 4) and FIG. 6 (SEQ ID NO:
• 6), lacking its associated signal peptide;
• (c) an extracellular domain of the polypeptide having the amino acid sequence selected from the group consisting of the amino acid sequence shown in FIG. 2 (SEQ ID NO:
• 2), FIG. 4 (SEQ ID NO:
• 4) and FIG. 6 (SEQ ID NO:
• 6), with its associated signal peptide;
• (d) an extracellular domain of the polypeptide having the amino acid sequence selected from the group consisting of the amino acid sequence shown in FIG. 2 (SEQ ID NO:
• 2), FIG. 4 (SEQ ID NO:
• 4) and FIG. 6 (SEQ ID NO:
• 6), lacking its associated signal peptide;
• (e) a polypeptide encoded by the nucleotide sequence selected from the group consisting of the nucleotide sequence shown in FIG. 1 (SEQ ID NO:
• 1), FIG. 3 (SEQ ID NO:3) and FIG. 5 (SEQ ID NO:
• 5);
• or
• (f) a polypeptide encoded by the full-length coding region of the nucleotide sequence selected from the group consisting of the nucleotide sequence shown in FIG. 1 (SEQ ID NO:
• 1), FIG. 3 (SEQ ID NO:3) and FIG. 5 (SEQ ID NO:
• 5), said method comprising contacting said cell with an antibody, oligopeptide or organic molecule that binds to said protein, the binding of said antibody, oligopeptide or organic molecule to said protein thereby causing an inhibition of growth of said cell.

A method of therapeutically treating a mammal having a cancerous tumor comprising cells that express a protein having at least 95% amino acid sequence identity to:

• (a) the polypeptide having the amino acid sequence selected from the group consisting of the amino acid sequence shown in FIG. 2 (SEQ ID NO:
• 2), FIG. 4 (SEQ ID NO:
• 4) and FIG. 6 (SEQ ID NO:
• 6);
• (b) the polypeptide having the amino acid sequence selected from the group consisting of the amino acid sequence shown in FIG. 2 (SEQ ID NO:
• 2), FIG. 4 (SEQ ID NO:
• 4) and FIG. 6 (SEQ ID NO:
• 6), lacking its associated signal peptide;
• (c) an extracellular domain of the polypeptide having the amino acid sequence selected from the group consisting of the amino acid sequence shown in FIG. 2 (SEQ ID NO:
• 2), FIG. 4 (SEQ ID NO:
• 4) and FIG. 6 (SEQ ID NO:
• 6), with its associated signal peptide;
• (d) an extracellular domain of the polypeptide having the amino acid sequence selected from the group consisting of the amino acid sequence shown in FIG. 2 (SEQ ID NO:
• 2), FIG. 4 (SEQ ID NO:
• 4) and FIG. 6 (SEQ ID NO:
• 6), lacking its associated signal peptide;
• (e) a polypeptide encoded by the nucleotide sequence selected from the group consisting of the nucleotide sequence shown in FIG. 1 (SEQ ID NO:
• 1), FIG. 3 (SEQ ID NO:3) and FIG. 5 (SEQ ID NO:
• 5);
• or
• (f) a polypeptide encoded by the full-length coding region of the nucleotide sequence selected from the group consisting of the nucleotide sequence shown in FIG. 1 (SEQ ID NO:
• 1), FIG. 3 (SEQ ID NO:3) and FIG. 5 (SEQ ID NO:
• 5), said method comprising administering to said mammal a therapeutically effective amount of an antibody, oligopeptide or organic molecule that binds to said protein, thereby effectively treating said mammal.

A method of determining the presence of a protein in a sample suspected of containing said protein, wherein said protein has at least 95% amino acid sequence identity to:

• (a) the polypeptide having the amino acid sequence selected from the group consisting of the amino acid sequence shown in FIG. 2 (SEQ ID NO:
• 2), FIG. 4 (SEQ ID NO:
• 4) and FIG. 6 (SEQ ID NO:
• 6);
• (b) the polypeptide having the amino acid sequence selected from the group consisting of the amino acid sequence shown in FIG. 2 (SEQ ID NO:
• 2), FIG. 4 (SEQ ID NO:
• 4) and FIG. 6 (SEQ ID NO:
• 6), lacking its associated signal peptide;
• (c) an extracellular domain of the polypeptide having the amino acid sequence selected from the group consisting of the amino acid sequence shown in FIG. 2 (SEQ ID NO:
• 2), FIG. 4 (SEQ ID NO:
• 4) and FIG. 6 (SEQ ID NO:
• 6), with its associated signal peptide;
• (d) an extracellular domain of the polypeptide having the amino acid sequence selected from the group consisting of the amino acid sequence shown in FIG. 2 (SEQ ID NO:
• 2), FIG. 4 (SEQ ID NO:
• 4) and FIG. 6 (SEQ ID NO:
• 6), lacking its associated signal peptide;
• (e) a polypeptide encoded by the nucleotide sequence selected from the group consisting of the nucleotide sequence shown in FIG. 1 (SEQ ID NO:
• 1), FIG. 3 (SEQ ID NO:3) and FIG. 5 (SEQ ID NO:
• 5);
• or
• (f) a polypeptide encoded by the full-length coding region of the nucleotide sequence selected from the group consisting of the nucleotide sequence shown in FIG. 1 (SEQ ID NO:
• 1), FIG. 3 (SEQ ID NO:3) and FIG. 5 (SEQ ID NO:
• 5), said method comprising exposing said sample to an antibody, oligopeptide or organic molecule that binds to said protein and determining binding of said antibody, oligopeptide or organic molecule to said protein in said sample, wherein binding of the antibody, oligopeptide or organic molecule to said protein is indicative of the presence of said protein in said sample.

A method for treating or preventing a cell proliferative disorder associated with increased expression or activity of a protein having at least 95% amino acid sequence identity to:

• (a) the polypeptide having the amino acid sequence selected from the group consisting of the amino acid sequence shown in FIG. 2 (SEQ ID NO:
• 2), FIG. 4 (SEQ ID NO:
• 4) and FIG. 6 (SEQ ID NO:
• 6);
• (b) the polypeptide having the amino acid sequence selected from the group consisting of the amino acid sequence shown in FIG. 2 (SEQ ID NO:
• 2), FIG. 4 (SEQ ID NO:
• 4) and FIG. 6 (SEQ ID NO:
• 6), lacking its associated signal peptide;
• (c) an extracellular domain of the polypeptide having the amino acid sequence selected from the group consisting of the amino acid sequence shown in FIG. 2 (SEQ ID NO:
• 2), FIG. 4 (SEQ ID NO:
• 4) and FIG. 6 (SEQ ID NO:
• 6) with its associated signal peptide;
• (d) an extracellular domain of the polypeptide having the amino acid sequence selected from the group consisting of the amino acid sequence shown in FIG. 2 (SEQ ID NO:
• 2), FIG. 4 (SEQ ID NO:
• 4) and FIG. 6 (SEQ ID NO:
• 6), lacking its associated signal peptide;
• (e) a polypeptide encoded by the nucleotide sequence selected from the group consisting of the nucleotide sequence shown in FIG. 1 (SEQ ID NO:
• 1), FIG. 3 (SEQ ID NO:3) and FIG. 5 (SEQ ID NO:
• 5);
• or
• (f) a polypeptide encoded by the full-length coding region of the nucleotide sequence selected from the group consisting of the nucleotide sequence shown in FIG. 1 (SEQ ID NO:
• 1), FIG. 3 (SEQ ID NO:3) and FIG. 5 (SEQ ID NO:
• 5), said method comprising administering to a subject in need of such treatment an effective amount of an antagonist of said protein, thereby effectively treating or preventing said cell proliferative disorder.

A method of binding an antibody, oligopeptide or organic molecule to a cell that expresses a protein having at least 95% amino acid sequence identity to:

• (a) the polypeptide having the amino acid sequence selected from the group consisting of the amino acid sequence shown in FIG. 2 (SEQ ID NO:
• 2), FIG. 4 (SEQ ID NO:
• 4) and FIG. 6 (SEQ ID NO:
• 6);
• (b) the polypeptide having the amino acid sequence selected from the group consisting of the amino acid sequence shown in FIG. 2 (SEQ ID NO:
• 2), FIG. 4 (SEQ ID NO:
• 4) and FIG. 6 (SEQ ID NO:
• 6), lacking its associated signal peptide;
• (c) an extracellular domain of the polypeptide having the amino acid sequence selected from the group consisting of the amino acid sequence shown in FIG. 2 (SEQ ID NO:
• 2), FIG. 4 (SEQ ID NO:
• 4) and FIG. 6 (SEQ ID NO:
• 6), with its associated signal peptide;
• (d) an extracellular domain of the polypeptide having the amino acid sequence selected from the group consisting of the amino acid sequence shown in FIG. 2 (SEQ ID NO:
• 2), FIG. 4 (SEQ ID NO:
• 4) and FIG. 6 (SEQ ID NO:
• 6), lacking its associated signal peptide;
• (e) a polypeptide encoded by the nucleotide sequence selected from the group consisting of the nucleotide sequence shown in FIG. 1 (SEQ ID NO:
• 1), FIG. 3 (SEQ ID NO:3) and FIG. 5 (SEQ ID NO:
• 5);
• or
• (f) a polypeptide encoded by the full-length coding region of the nucleotide sequence selected from the group consisting of the nucleotide sequence shown in FIG. 1 (SEQ ID NO:
• 1), FIG. 3 (SEQ ID NO:3) and FIG. 5 (SEQ ID NO:
• 5), said method comprising contacting said cell with an antibody, oligopeptide or organic molecule that binds to said protein and allowing the binding of the antibody, oligopeptide or organic molecule to said protein to occur, thereby binding said antibody, oligopeptide or organic molecule to said cell.

A method for inhibiting the growth of a cell, wherein the growth of said cell is at least in part dependent upon a growth potentiating effect of a protein having at least 95% amino acid sequence identity to:

• (a) the polypeptide having the amino acid sequence selected from the group consisting of the amino acid sequence shown in FIG. 2 (SEQ ID NO:
• 2), FIG. 4 (SEQ ID NO:
• 4) and FIG. 6 (SEQ ID NO:
• 6);
• (b) the polypeptide having the amino acid sequence selected from the group consisting of the amino acid sequence shown in FIG. 2 (SEQ ID NO:
• 2), FIG. 4 (SEQ ID NO:
• 4) and FIG. 6 (SEQ ID NO:
• 6), lacking its associated signal peptide;
• (c) an extracellular domain of the polypeptide having the amino acid sequence selected from the group consisting of the amino acid sequence shown in FIG. 2 (SEQ ID NO:
• 2), FIG. 4 (SEQ ID NO:
• 4) and FIG. 6 (SEQ ID NO:
• 6), with its associated signal peptide;
• (d) an extracellular domain of the polypeptide having the amino acid sequence selected from the group consisting of the amino acid sequence shown in FIG. 2 (SEQ ID NO:
• 2), FIG. 4 (SEQ ID NO:
• 4) and FIG. 6 (SEQ ID NO:
• 6), lacking its associated signal peptide;
• (e) a polypeptide encoded by the nucleotide sequence selected from the group consisting of the nucleotide sequence shown in FIG. 1 (SEQ ID NO:
• 1), FIG. 3 (SEQ ID NO:3) and FIG. 5 (SEQ ID NO:
• 5);
• or
• (f) a polypeptide encoded by the full-length coding region of the nucleotide sequence selected from the group consisting of the nucleotide sequence shown in FIG. 1 (SEQ ID NO:
• 1), FIG. 3 (SEQ ID NO:3) and FIG. 5 (SEQ ID NO:
• 5), said method comprising contacting said protein with an antibody, oligopeptide or organic molecule that binds to said protein, there by inhibiting the growth of said cell.

A method of therapeutically treating a tumor in a mammal, wherein the growth of said tumor is at least in part dependent upon a growth potentiating effect of a protein having at least 95% amino acid sequence identity to:

• (a) the polypeptide having the amino acid sequence selected from the group consisting of the amino acid sequence shown in FIG. 2 (SEQ ID NO:
• 2), FIG. 4 (SEQ ID NO:
• 4) and FIG. 6 (SEQ ID NO:
• 6);
• (b) the polypeptide having the amino acid sequence selected from the group consisting of the amino acid sequence shown in FIG. 2 (SEQ ID NO:
• 2), FIG. 4 (SEQ ID NO:
• 4) and FIG. 6 (SEQ ID NO:
• 6), lacking its associated signal peptide;
• (c) an extracellular domain of the polypeptide having the amino acid sequence selected from the group consisting of the amino acid sequence shown in FIG. 2 (SEQ ID NO:
• 2), FIG. 4 (SEQ ID NO:
• 4) and FIG. 6 (SEQ ID NO:
• 6), with its associated signal peptide;
• (d) an extracellular domain of the polypeptide having the amino acid sequence selected from the group consisting of the amino acid sequence shown in FIG. 2 (SEQ ID NO:
• 2), FIG. 4 (SEQ ID NO:
• 4) and FIG. 6 (SEQ ID NO:
• 6), lacking its associated signal peptide;
• (e) a polypeptide encoded by the nucleotide sequence selected from the group consisting of the nucleotide sequence shown in FIG. 1 (SEQ ID NO:
• 1), FIG. 3 (SEQ ID NO:3) and FIG. 5 (SEQ ID NO:
• 5);
• or
• (f) a polypeptide encoded by the full-length coding region of the nucleotide sequence selected from the group consisting of the nucleotide sequence shown in FIG. 1 (SEQ ID NO:
• 1), FIG. 3 (SEQ ID NO:3) and FIG. 5 (SEQ ID NO:
• 5), said method comprising contacting said protein with an antibody, oligopeptide or organic molecule that binds to said protein, thereby effectively treating said tumor.

A method of diagnosing the presence of a tumor in a mammal, said method comprising detecting the presence of cells expressing a polypeptide comprising an amino acid sequence having at least 95% amino acid sequence identity to:

• (a) the polypeptide having the amino acid sequence selected from the group consisting of the amino acid sequence shown in FIG. 2 (SEQ ID NO:
• 2), FIG. 4 (SEQ ID NO:
• 4) and FIG. 6 (SEQ ID NO:
• 6);
• (b) the polypeptide having the amino acid sequence selected from the group consisting of the amino acid sequence shown in FIG. 2 (SEQ ID NO:
• 2), FIG. 4 (SEQ ID NO:
• 4) and FIG. 6 (SEQ ID NO:
• 6), lacking its associated signal peptide;
• (c) an extracellular domain of the polypeptide having the amino acid sequence selected from the group consisting of the amino acid sequence shown in FIG. 2 (SEQ ID NO:
• 2), FIG. 4 (SEQ ID NO:
• 4) and FIG. 6 (SEQ ID NO:
• 6), with its associated signal peptide;
• (d) an extracellular domain of the polypeptide having the amino acid sequence selected from the group consisting of the amino acid sequence shown in FIG. 2 (SEQ ID NO:
• 2), FIG. 4 (SEQ ID NO:
• 4) and FIG. 6 (SEQ ID NO:
• 6), lacking its associated signal peptide;
• (e) a polypeptide encoded by the nucleotide sequence selected from the group consisting of the nucleotide sequence shown in FIG. 1 (SEQ ID NO:
• 1), FIG. 3 (SEQ ID NO:3) and FIG. 5 (SEQ ID NO:
• 5);
• or
• (f) a polypeptide encoded by the full-length coding region of the nucleotide sequence selected from the group consisting of the nucleotide sequence shown in FIG. 1 (SEQ ID NO:
• 1), FIG. 3 (SEQ ID NO:3) and FIG. 5 (SEQ ID NO:
• 5), said method comprising contacting a test sample of tissue cells from said mammal with an antibody, oligopeptide or organic molecule that binds to said protein and detecting the formation of a complex between said antibody, oligopeptide or organic molecule, wherein an increased number of cells demonstrating said complex formation, as compared to a control sample, is indicative of the presence of a tumor in said mammal.

A method of detecting the presence of cells in a sample suspected of containing said cells, said method comprising detecting said cells by detecting cells expressing a polypeptide comprising an amino acid sequence having at least 95% amino acid sequence identity to:

• (a) the polypeptide having the amino acid sequence selected from the group consisting of the amino acid sequence shown in FIG. 2 (SEQ ID NO:
• 2), FIG. 4 (SEQ ID NO:
• 4) and FIG. 6 (SEQ ID NO:
• 6);
• (b) the polypeptide having the amino acid sequence selected from the group consisting of the amino acid sequence shown in FIG. 2 (SEQ ID NO:
• 2), FIG. 4 (SEQ ID NO:
• 4) and FIG. 6 (SEQ ID NO:
• 6), lacking its associated signal peptide;
• (c) an extracellular domain of the polypeptide having the amino acid sequence selected from the group consisting of the amino acid sequence shown in FIG. 2 (SEQ ID NO:
• 2), FIG. 4 (SEQ ID NO:
• 4) and FIG. 6 (SEQ ID NO:
• 6), with its associated signal peptide;
• (d) an extracellular domain of the polypeptide having the amino acid sequence selected from the group consisting of the amino acid sequence shown in FIG. 2 (SEQ ID NO:
• 2), FIG. 4 (SEQ ID NO:
• 4) and FIG. 6 (SEQ ID NO:
• 6), lacking its associated signal peptide;
• (e) a polypeptide encoded by the nucleotide sequence selected from the group consisting of the nucleotide sequence shown in FIG. 1 (SEQ ID NO:
• 1), FIG. 3 (SEQ ID NO:3) and FIG. 5 (SEQ ID NO:
• 5);
• or
• (f) a polypeptide encoded by the full-length coding region of the nucleotide sequence selected from the group consisting of the nucleotide sequence shown in FIG. 1 (SEQ ID NO:
• 1), FIG. 3 (SEQ ID NO:3) and FIG. 5 (SEQ ID NO:
• 5), said method comprising contacting said sample with an antibody, oligopeptide or organic molecule that binds to said protein and detecting the formation of a complex between said antibody, oligopeptide or organic molecule and said protein, wherein the formation of a complex indicates the presence of said cell.